Article Information
History
- May 9, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Fulvia Mazzaferri1,
- Massimo Mirandola1,
- Alessia Savoldi1,
- Pasquale De Nardo1,
- Matteo Morra1,
- Maela Tebon1,
- Maddalena Armellini1,
- Giulia De Luca1,
- Lucrezia Calandrino2,
- Lolita Sasset2,
- Denise D’Elia3,
- Emanuela Sozio3,
- Elisa Danese4,
- Davide Gibellini5,
- Isabella Monne6,
- Giovanna Scroccaro7,
- Nicola Magrini8,
- Annamaria Cattelan2,
- Carlo Tascini3,
- MANTICO Working Group and
- Evelina Tacconelli1,*
- ↵*Corresponding author
Evelina Tacconelli, Infectious Diseases Division, Department of Diagnostics and Public Health, University of Verona Piazzale Scuro 10, 37134, Verona, Italy, evelina.tacconelli{at}univr.it
- 1Infectious Diseases Division, Department of Diagnostics and Public Health, University of Verona, Verona, Italy
- 2Infectious Disease Unit, Padova University Hospital, Padua, Italy
- 3Infectious Diseases Division, Department of Medicine, University of Udine and Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy
- 4Section of Clinical Biochemistry, Department of Neuroscience, Biomedicine and Movement, University of Verona, Verona, Italy
- 5Microbiology and Virology Unit, Department of Diagnostics and Public Health, University of Verona, Verona, Italy
- 6Viral genomics and transcriptomics Laboratory, Istituto Zooprofilattico Sperimentale delle Venezie, Legnaro, Italy
- 7Direzione Farmaceutico, Protesica, Dispositivi Medici, Regione del Veneto, Venice, Italy
- 8Italian Medicines Agency, Rome, Italy
Posted May 09, 2022.
Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron Variant of Concern
